NovoCure Limited financials
$15.95−0.25%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $183.6M | $174.1M | $174.3M | $167.2M | $158.8M | $155.0M | $161.3M | $155.1M | $150.4M | $138.5M | $133.8M | $127.3M |
| Gross profit | $142.5M | $135.1M | $132.2M | $122.5M | $117.3M | $116.5M | $127.8M | $119.7M | $115.7M | $104.8M | $101.2M | $95.2M |
| Gross margin | 77.6% | 77.6% | 75.8% | 73.2% | 73.9% | 75.1% | 79.2% | 77.2% | 77.0% | 75.7% | 75.7% | 74.8% |
| Operating income | -$10.6M | -$67.4M | -$40.4M | -$36.0M | -$39.5M | -$37.9M | -$63.3M | -$32.1M | -$33.6M | -$41.5M | -$51.7M | -$58.2M |
| Net income | -$15.7M | -$71.1M | -$24.5M | -$37.3M | -$40.1M | -$34.3M | -$65.9M | -$30.6M | -$33.4M | -$38.8M | -$47.1M | -$49.5M |
| Net margin | −8.5% | −40.9% | −14.1% | −22.3% | −25.3% | −22.1% | −40.9% | −19.7% | −22.2% | −28.0% | −35.2% | −38.9% |
| Diluted EPS | $-0.13 | $-0.62 | $-0.22 | $-0.33 | $-0.36 | $-0.31 | $-0.61 | $-0.28 | $-0.31 | $-0.36 | $-0.44 | $-0.46 |
| EBITDA | -$6.3M | -$63.3M | -$36.2M | -$32.4M | -$36.1M | -$34.5M | -$60.2M | -$29.6M | -$30.7M | -$38.7M | -$51.7M | -$55.4M |
| Operating cash flow | $8.1M | -$13.5M | -$18.0M | $20.6M | -$15.9M | -$35.7M | -$3.5M | $10.4M | -$1.7M | -$31.6M | -$14.6M | -$19.3M |
| Free cash flow | $1.2M | -$18.7M | -$22.9M | $14.9M | -$21.4M | -$46.3M | -$12.4M | -$307.0K | -$13.2M | -$43.4M | -$21.4M | -$26.6M |
| Diluted shares | 116.0M | 114.1M | 112.1M | 111.9M | 111.6M | 110.3M | 108.1M | 108.2M | 107.7M | 107.3M | 106.8M | 106.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $93.7M | $87.5M | $93.5M | $342.1M | $149.6M | $127.3M |
| Short-term investments | $346.9M | $344.5M | $354.1M | $691.4M | $761.9M | $801.9M |
| Total debt | $195.9M | $195.5M | $195.0M | $755.3M | $657.4M | $656.4M |
| Total assets | $795.2M | $787.9M | $804.3M | $1.36B | $1.25B | $1.25B |
| Total liabilities | $457.1M | $457.2M | $463.9M | $1.02B | $896.4M | $886.9M |
| Shareholders' equity | $338.1M | $330.7M | $340.5M | $341.3M | $349.4M | $362.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology